LMWH bridging therapy redundant for stroke patients in DOAC era

The use of low-molecular-weight heparin bridging therapy for secondary prevention after an acute stroke is being questioned after new evidence showed increased risks of ischaemic recurrence and intracerebral bleeding. It may be preferable to use direct acting oral anticoagulants (DOACs) that have a rapid onset and are reversible rather than slow-onset vitamin K antagonists such ...

Already a member?

Login to keep reading.

© 2021 the limbic